| To: Kirk © who wrote (116) | 7/13/2019 8:27:35 PM | | From: Rarebird | | | | | Thanks for the post. It served as a reminder to get the first of the two new Shingle's shots, which I did today. I took a Shingles shot 6 years ago, but that one was only supposed to last for 5 years. Last year, I tried to get the new Shingle's shot, but it wasn't in stock at the pharmacy I checked . Since then, I forgot all about it till I read your post. |
| | Agenus (AGEN) | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last ReadRead Replies (1) |
|
| To: Rarebird who wrote (117) | 7/15/2019 6:52:46 AM | | From: Rarebird | | | | I feel much better now. I took the Shingrix shot 3pm ( PST) on Saturday. I felt fine the rest of the day. But I woke up Sunday morning with a headache and feeling tired and weak. I pushed myself to go jogging with my dog for an hour. I came back feeling worse. I ran a low grade fever for a few hours. I laid in bed and slept most of the day. Come early evening, I felt a bit better. This morning I am considerably better. I am not tired or weak, slight headache. It is a rough shot. Tylenol helps.
Not looking forward to the second shot. But I will take it. |
| | Agenus (AGEN) | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last ReadRead Replies (2) |
|
| To: Rarebird who wrote (118) | 7/15/2019 10:13:36 AM | | From: Kirk © | | | | That sounds similar to my results.
I got my first Shingrix shot on July 1st around 10 AM. No side effects other than a tiny bit of soreness at the injection site. I used my pole chain saw and heavy duty pruner to cut and prune trees for 1.5 hrs in the afternoon.
July 2nd I felt "off" with sore muscles much like the flu, the injection site was reddish like a bruise and was slightly painful to the touch. I may have been a bit more tired than usual, especially since I had not windsurfed the day before but gardening can cause me to be tired and sore the next day. Running hurts my knees so I did a 1 hr 3.5 mile hike in the afternoon. It didn't seem to slow me down and it was nice to get outside and my mind off feeling a bit sore.
July 3rd I felt great and windsurfed in the afternoon for an hour an 8 minutes covering 13.5 miles with a 3.3 training effect.
July 4th the wind was better and I windsurfed 22.5 miles in 87 minutes with a 3.8 training effect.
My girlfriend had a similar experience with her first and second doses.
I too plan to get the second shot in 4 months after windsurfing season ends so I don't miss a possible good day windsurfing due to the 2nd day flu-like symptoms.
shingrix.com |
| | Agenus (AGEN) | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last ReadRead Replies (1) |
|
| To: Rarebird who wrote (118) | 7/18/2019 2:20:01 PM | | From: Kirk © | | | | Nice hire from a "real company"....
Agenus Appoints Don Vidic as Vice President and Head of Commercial The appointment comes as Agenus is preparing for its first BLA filing in 2020 and evolving towards a commercial company
LEXINGTON, Mass., July 18, 2019 / PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a broad pipeline of novel clinical and preclinical stage checkpoint antibodies, cell therapies and neoantigen vaccines, today announced the appointment of Don Vidic as Vice President, Head of Commercial.
"Don has deep expertise in market access and distribution strategies and shares our commitment to disruptive commercial models designed to provide access to all patients who need our products," said Garo H. Armen, Ph.D., Chairman and CEO of Agenus. "We have built a unique ecosystem which has allowed us to innovate with speed and set new records in drug discovery and development. We are on track to submit our first BLA filing for our lead CTLA-4 and PD-1 molecules in 2020. Our clinical stage next generation CTLA-4 (AGEN1181) and our allogeneic cell therapies are also progressing rapidly. I'm excited to welcome Don to lead our commercial launch efforts at this very exciting time for our company."
Don Vidic is an industry veteran with more than 30 years of expertise in specialty pharma distribution, managed care, as well as physician and pharmacy services. Prior to joining Agenus, Don served as the Chief Pharmacy and Growth Officer at Walgreens Boots Alliance and as the General Manager and VP at McKesson, currently the largest oncology specialty pharma, where he managed all trade, managed care, physician sales and pharmacy services.
"Agenus has an outstanding pipeline of products and a deep commitment to bringing high impact products to patients battling cancer," said Mr. Vidic. "My work has focused on getting patients the products they need, quickly. I will build on the innovative standard Agenus has already set and cut through the current complex networks to get our products to patients and build value for our stakeholders."
About Agenus
Agenus is a clinical-stage immuno-oncology company focused on the discovery and development of therapies that engage the body's immune system to fight cancer. The Company's vision is to expand the patient populations benefiting from cancer immunotherapy by pursuing combination approaches that leverage a broad repertoire of antibody therapeutics and proprietary cancer vaccine platforms. The Company is equipped with a suite of antibody discovery platforms and a state-of-the-art GMP manufacturing facility with the capacity to support early phase clinical programs. Agenus is headquartered in Lexington, MA. For more information, please visit www.agenusbio.com; information that may be important to investors will be routinely posted on our website.
Forward-Looking Statements
This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements regarding Agenus' clinical trial plans and activities and timelines for filing INDs, filing BLAs and initiating commercial launch of candidates, if approved. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include, among others, the factors described under the Risk Factors section of our most recent Quarterly Report on Form 10-Q or Annual Report on Form 10-K filed with the Securities and Exchange Commission. Agenus cautions investors not to place considerable reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this press release, and Agenus undertakes no obligation to update or revise the statements, other than to the extent required by law. All forward-looking statements are expressly qualified in their entirety by this cautionary statement.
Contact:
Agenus Inc.
Jennifer Buell, PhD
781-674-4420
Jennifer.Buell@agenusbio.com
1Through AgenTus Therapeutics, a subsidiary of Agenus
News Release Issued: Jul 18, 2019 (2:00pm EDT)
To view this release online and get more information about Agenus Bio InvestorRoom visit: investor.agenusbio.com
SOURCE Agenus Inc. |
| | Agenus (AGEN) | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last Read |
|
| To: Kirk © who wrote (119) | 9/30/2019 7:43:23 AM | | From: Rarebird | | | | I took the second Shingles shot on Saturday. My reaction was worse than the first time. I ran a low grade fever all day Sunday, with a heavy head ( headache), slight sore throat and a stuffed nose with sneezing. It felt like the initial stages of the flu. This morning I am improved with no fever. I will see how I feel after I come back from my one hour jog with my dog.
Worse shot I ever had in terms of after affects. First shot affects was mild in comparison to this. |
| | Agenus (AGEN) | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last ReadRead Replies (7) |
|
| To: Rarebird who wrote (122) | 11/11/2019 10:41:32 AM | | From: Kirk © | | | | | It is interesting how much the side effects vary. I got my 2nd shot last Thursday, was tired like the flu on Friday and mostly back to normal on Saturday. |
| | Agenus (AGEN) | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last Read |
|
| To: Alejandroo Green who wrote () | 11/11/2019 10:45:39 AM | | From: Kirk © | | | | News Release Issued: Nov 11, 2019 (8:00am EST)
Agenus receives $10M from UroGen Pharma for rights to Zalifrelimab (CTLA-4) for intravesical treatment of urinary tract cancers
- UroGen receives rights to zalifrelimab to be used in its proprietary sustained release formulation for
patients with high-grade non-muscle invasive bladder cancer LEXINGTON, Mass., Nov. 11, 2019 / PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies, adoptive cell therapies1 and cancer vaccines, announced today that it received $10M upfront for a License Agreement with UroGen Pharma Ltd. Under the agreement Agenus is providing access to zalifrelimab (AGEN1884, anti-CTLA-4 antibody) for use with UroGen's sustained release technology for intravesical delivery in patients with urinary tract cancers. Agenus is conducting clinical trials for zalifrelimab in combination with Agenus' anti-PD-1 antibody balstilimab (AGEN2034) for a planned BLA filing in cervical cancer. In addition, zalifrelimab is being evaluated as a monotherapy in PD-1 refractory patients.
Under the terms of the agreement, in addition to the $10 million upfront payment, Agenus is eligible to receive up to $200M in potential development, regulatory and commercial milestones, as well as 14-20% royalties on net sales.
"In our ongoing clinical trials, zalifrelimab and the combination of zalifrelimab plus balstilimab (AGEN2034, anti-PD-1 antibody) have delivered durable as well as curative responses in patients across a broad range of tumors. Agenus is developing the combination in multiple solid tumors with a first planned BLA filing in 2020," said Garo H. Armen, Ph.D., Chairman and CEO of Agenus. "We are enthusiastic to expand the benefit of zalifrelimab through intravesical delivery to patients with urinary tract cancer in this exciting collaboration with UroGen."
About Agenus
Agenus is a clinical-stage immuno-oncology company focused on the discovery and development of therapies that engage the body's immune system to fight cancer. The Company's vision is to expand the patient populations benefiting from cancer immunotherapy with combination approaches that leverage a broad repertoire of antibody therapeutics, adoptive cell therapies (through its AgenTus Therapeutics subsidiary) and its proprietary cancer vaccine platforms. Agenus has a suite of antibody discovery platforms and a state-of-the-art GMP manufacturing facility with the capacity to support early phase clinical programs. Agenus is headquartered in Lexington, MA. For more information, please visit www.agenusbio.com and our twitter handle @agenus_bio. Information that may be important to investors will be routinely posted on our website and twitter.
Forward-Looking Statements
This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements regarding Agenus' clinical development and regulatory plans and timelines and the anticipated benefits of the UroGen collaboration. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include, among others, the factors described under the Risk Factors section of our most recent Quarterly Report on Form 10-Q or Annual Report on Form 10-K filed with the Securities and Exchange Commission. Agenus cautions investors not to place considerable reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this press release, and Agenus undertakes no obligation to update or revise the statements, other than to the extent required by law. All forward-looking statements are expressly qualified in their entirety by this cautionary statement.
Contact:
Agenus Inc.
Jennifer Buell, PhD
781-674-4420
Jennifer.Buell@agenusbio.com
1Through AgenTus Therapeutics, a subsidiary of Agenus
SOURCE Agenus Inc.
To view this release online and get more information about Agenus Bio InvestorRoom visit: investor.agenusbio.com |
| | Agenus (AGEN) | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last Read |
|
| To: Rarebird who wrote (122) | 12/19/2019 11:53:38 AM | | From: Kirk © | | | | News Release Issued: Dec 19, 2019 (7:30am EST)
Agenus Commences Combination Trial of its Next-Gen CTLA-4 with its PD-1 Antibody
LEXINGTON, Mass., Dec. 19, 2019 / PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies, adoptive cell therapies1 and cancer vaccines, today announced the first patient dosed with AGEN1181, an anti-CTLA-4 antibody, in combination with balstilimab, Agenus' PD-1 inhibitor. Agenus began this study as a monotherapy in patients with advanced solid tumors within a Phase 1 dose escalation study (NCT03860272) in April 2019.
The first patients to be treated with AGEN1181 as a monotherapy as well as the combination trial with PD-1 were dosed by Dr. Steven O'Day, Executive Director of the John Wayne Cancer Institute & Cancer Clinic, and a pioneer in delivering immune therapies to patients with cancer.
"AGEN1181, with its potential for enhanced immune activation and tumor fighting abilities, may bring superior benefit to a broader group of patients compared to first generation anti-CTLA-4 antibodies," said Dr. O'Day. "The pre-clinical data suggest the superiority of this molecule as a monotherapy and in combination with anti-PD-1, like balstilimab. Furthermore, AGEN1181 was designed to bring benefit to a broad population of patients both who respond to first generation molecules and those who do not respond due to a genetic polymorphism. Expanding the important immune priming benefit of CTLA-4 to a broad group of patients would be outstanding. I am thrilled to be working with this compound."
Balstilimab, the company's proprietary anti-PD-1 antibody, is currently being evaluated as a monotherapy and in combination with zalfrelimab (a first generation CTLA-4) in trials designed to support a planned BLA filing in 2020 for patients with relapsed/refractory cervical cancer.
This expanded trial is another example of Agenus' ability to rapidly advance its novel pipeline. Next-Gen CTLA-4 is a novel antibody from Agenus' discovery engine, and with its own PD-1 molecule, Agenus has been able to move this important combination into the clinic with a high sense of urgency.
About AGEN1181
AGEN1181, a novel 'Fc engineered' antibody with potential for enhanced anti-tumor functions, is specifically designed to boost cancer killing immune cells and deplete intratumoral regulatory T cells that promote immune evasion. By enhancing binding to a specific Fc receptor, Fc?RIIIA, on antigen-presenting cells or natural killer cells, AGEN1181 significantly enhances the therapeutic potential of anti-CTLA-4 therapy leveraging novel mechanisms that are not captured by the first-generation anti-CTLA-4 therapies. AGEN1181's Fc engineered backbone improves the cross-talk between antigen-presenting cells and T cells, to enable optimal T cell priming, activation and formation of durable memory responses. Moreover, AGEN1181 enhanced binding to Fc?RIIIA, significantly increases the potential to deplete intratumoral regulatory T cells, a significant barrier to successful anti-cancer immune responses. Notably, AGEN1181 is engineered to strongly bind both the low affinity and high affinity Fc?RIIIA polymorphisms, unlike first generation molecules which weakly bind the low affinity polymorphism. AGEN1181 is designed to expand the benefit to an additional ~40% of patients with the low affinity polymorphism and enhance the benefits of CTLA-4 in all patients.
About Agenus
Agenus is a clinical-stage immuno-oncology company focused on the discovery and development of therapies that engage the body's immune system to fight cancer. The Company's vision is to expand the patient populations benefiting from cancer immunotherapy with combination approaches that leverage a broad repertoire of antibody therapeutics, adoptive cell therapies (through its AgenTus Therapeutics subsidiary) and its proprietary cancer vaccine platforms. Agenus has a suite of antibody discovery platforms and a state-of-the-art GMP manufacturing facility with the capacity to support early phase clinical programs. Agenus is headquartered in Lexington, MA. For more information, please visit www.agenusbio.com and our twitter handle @agenus_bio. Information that may be important to investors will be routinely posted on our website and twitter.
Forward-Looking Statements
This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements regarding Agenus' clinical development and regulatory plans and timelines and the potential therapeutic benefit of AGEN1181. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include, among others, the factors described under the Risk Factors section of our most recent Quarterly Report on Form 10-Q or Annual Report on Form 10-K filed with the Securities and Exchange Commission. Agenus cautions investors not to place considerable reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this press release, and Agenus undertakes no obligation to update or revise the statements, other than to the extent required by law. All forward-looking statements are expressly qualified in their entirety by this cautionary statement.
Contact:
Agenus Inc.
Jennifer Buell, PhD
Jennifer.Buell@agenusbio.com
1Through AgenTus Therapeutics, a subsidiary of Agenus
SOURCE Agenus
To view this release online and get more information about Agenus Bio InvestorRoom visit: investor.agenusbio.com |
| | Agenus (AGEN) | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last Read |
|
| |
